Transcriptional Regulation of Plasminogen Activator Inhibitor Type 1 Gene by Insulin: Insights into the Signaling Pathway

Cristina Banfi, Per Eriksson, Giovanna Giandomenico, Luciana Mussoni, Luigi Sironi, Anders Hamsten, Elena Tremoli

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Impairment of the fibrinolytic system, caused primarily by increases in the plasma levels of plasminogen activator inhibitor (PAI) type 1, are frequently found in diabetes and the insulin-resistance syndrome. Among the factors responsible for the increases of PAI-1, insulin has recently attracted attention. In this study, we analyzed the effects of insulin on PAI-1 biosynthesis in HepG2 cells, paying particular attention to the signaling network evoked by this hormone. Experiments performed in CHO cells overexpressing the insulin receptor indicate that insulin increases PAI-1 gene transcription through interaction with its receptor. By using inhibitors of the different signaling pathways evoked by insulin-receptor binding, it has been shown that the biosynthesis of PAI-1 is due to phosphatidylinositol (PI) 3-kinase activation, followed by protein kinase C and ultimately by mitogen-activated protein (MAP) kinase activation and extracellular signal-regulated kinase 2 phosphorylation. We also showed that this pathway is Ras-independent. Transfection of HepG2 cells with several truncations of the PAI-1 promoter coupled to a CAT gene allowed us to recognize two major response elements located in the regions between -804 and -708 and between -211 and -54. Electrophoretic mobility shift assay identified three binding sites for insulin-induced factors, all colocalized with putative Sp1 binding sites. Using supershifting antibodies, the binding of Sp1 could only be confirmed at the binding site located just upstream from the transcription start site of the PAI-1 promoter. A construct comprising four tandem repeat copies of the -93/-62 region of the PAI-1 promoter linked to CAT was transcriptionally activated in Hep62 cells by insulin. These results outline the central role of MAP kinase activation in the regulation of PAI-1 induced by insulin.

Original languageEnglish
Pages (from-to)1522-1530
Number of pages9
JournalDiabetes
Volume50
Issue number7
Publication statusPublished - Jul 2001

Fingerprint

Plasminogen Activator Inhibitor 1
Insulin
Genes
Binding Sites
Insulin Receptor
Hep G2 Cells
Mitogen-Activated Protein Kinases
Phosphatidylinositol 3-Kinase
Tandem Repeat Sequences
CHO Cells
Transcription Initiation Site
Mitogen-Activated Protein Kinase 1
Response Elements
Electrophoretic Mobility Shift Assay
Protein Kinase C
Transfection
Insulin Resistance
Phosphorylation
Hormones
Antibodies

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Transcriptional Regulation of Plasminogen Activator Inhibitor Type 1 Gene by Insulin : Insights into the Signaling Pathway. / Banfi, Cristina; Eriksson, Per; Giandomenico, Giovanna; Mussoni, Luciana; Sironi, Luigi; Hamsten, Anders; Tremoli, Elena.

In: Diabetes, Vol. 50, No. 7, 07.2001, p. 1522-1530.

Research output: Contribution to journalArticle

Banfi, Cristina ; Eriksson, Per ; Giandomenico, Giovanna ; Mussoni, Luciana ; Sironi, Luigi ; Hamsten, Anders ; Tremoli, Elena. / Transcriptional Regulation of Plasminogen Activator Inhibitor Type 1 Gene by Insulin : Insights into the Signaling Pathway. In: Diabetes. 2001 ; Vol. 50, No. 7. pp. 1522-1530.
@article{f2faabd694734f28a74925c83b6c9f52,
title = "Transcriptional Regulation of Plasminogen Activator Inhibitor Type 1 Gene by Insulin: Insights into the Signaling Pathway",
abstract = "Impairment of the fibrinolytic system, caused primarily by increases in the plasma levels of plasminogen activator inhibitor (PAI) type 1, are frequently found in diabetes and the insulin-resistance syndrome. Among the factors responsible for the increases of PAI-1, insulin has recently attracted attention. In this study, we analyzed the effects of insulin on PAI-1 biosynthesis in HepG2 cells, paying particular attention to the signaling network evoked by this hormone. Experiments performed in CHO cells overexpressing the insulin receptor indicate that insulin increases PAI-1 gene transcription through interaction with its receptor. By using inhibitors of the different signaling pathways evoked by insulin-receptor binding, it has been shown that the biosynthesis of PAI-1 is due to phosphatidylinositol (PI) 3-kinase activation, followed by protein kinase C and ultimately by mitogen-activated protein (MAP) kinase activation and extracellular signal-regulated kinase 2 phosphorylation. We also showed that this pathway is Ras-independent. Transfection of HepG2 cells with several truncations of the PAI-1 promoter coupled to a CAT gene allowed us to recognize two major response elements located in the regions between -804 and -708 and between -211 and -54. Electrophoretic mobility shift assay identified three binding sites for insulin-induced factors, all colocalized with putative Sp1 binding sites. Using supershifting antibodies, the binding of Sp1 could only be confirmed at the binding site located just upstream from the transcription start site of the PAI-1 promoter. A construct comprising four tandem repeat copies of the -93/-62 region of the PAI-1 promoter linked to CAT was transcriptionally activated in Hep62 cells by insulin. These results outline the central role of MAP kinase activation in the regulation of PAI-1 induced by insulin.",
author = "Cristina Banfi and Per Eriksson and Giovanna Giandomenico and Luciana Mussoni and Luigi Sironi and Anders Hamsten and Elena Tremoli",
year = "2001",
month = "7",
language = "English",
volume = "50",
pages = "1522--1530",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "7",

}

TY - JOUR

T1 - Transcriptional Regulation of Plasminogen Activator Inhibitor Type 1 Gene by Insulin

T2 - Insights into the Signaling Pathway

AU - Banfi, Cristina

AU - Eriksson, Per

AU - Giandomenico, Giovanna

AU - Mussoni, Luciana

AU - Sironi, Luigi

AU - Hamsten, Anders

AU - Tremoli, Elena

PY - 2001/7

Y1 - 2001/7

N2 - Impairment of the fibrinolytic system, caused primarily by increases in the plasma levels of plasminogen activator inhibitor (PAI) type 1, are frequently found in diabetes and the insulin-resistance syndrome. Among the factors responsible for the increases of PAI-1, insulin has recently attracted attention. In this study, we analyzed the effects of insulin on PAI-1 biosynthesis in HepG2 cells, paying particular attention to the signaling network evoked by this hormone. Experiments performed in CHO cells overexpressing the insulin receptor indicate that insulin increases PAI-1 gene transcription through interaction with its receptor. By using inhibitors of the different signaling pathways evoked by insulin-receptor binding, it has been shown that the biosynthesis of PAI-1 is due to phosphatidylinositol (PI) 3-kinase activation, followed by protein kinase C and ultimately by mitogen-activated protein (MAP) kinase activation and extracellular signal-regulated kinase 2 phosphorylation. We also showed that this pathway is Ras-independent. Transfection of HepG2 cells with several truncations of the PAI-1 promoter coupled to a CAT gene allowed us to recognize two major response elements located in the regions between -804 and -708 and between -211 and -54. Electrophoretic mobility shift assay identified three binding sites for insulin-induced factors, all colocalized with putative Sp1 binding sites. Using supershifting antibodies, the binding of Sp1 could only be confirmed at the binding site located just upstream from the transcription start site of the PAI-1 promoter. A construct comprising four tandem repeat copies of the -93/-62 region of the PAI-1 promoter linked to CAT was transcriptionally activated in Hep62 cells by insulin. These results outline the central role of MAP kinase activation in the regulation of PAI-1 induced by insulin.

AB - Impairment of the fibrinolytic system, caused primarily by increases in the plasma levels of plasminogen activator inhibitor (PAI) type 1, are frequently found in diabetes and the insulin-resistance syndrome. Among the factors responsible for the increases of PAI-1, insulin has recently attracted attention. In this study, we analyzed the effects of insulin on PAI-1 biosynthesis in HepG2 cells, paying particular attention to the signaling network evoked by this hormone. Experiments performed in CHO cells overexpressing the insulin receptor indicate that insulin increases PAI-1 gene transcription through interaction with its receptor. By using inhibitors of the different signaling pathways evoked by insulin-receptor binding, it has been shown that the biosynthesis of PAI-1 is due to phosphatidylinositol (PI) 3-kinase activation, followed by protein kinase C and ultimately by mitogen-activated protein (MAP) kinase activation and extracellular signal-regulated kinase 2 phosphorylation. We also showed that this pathway is Ras-independent. Transfection of HepG2 cells with several truncations of the PAI-1 promoter coupled to a CAT gene allowed us to recognize two major response elements located in the regions between -804 and -708 and between -211 and -54. Electrophoretic mobility shift assay identified three binding sites for insulin-induced factors, all colocalized with putative Sp1 binding sites. Using supershifting antibodies, the binding of Sp1 could only be confirmed at the binding site located just upstream from the transcription start site of the PAI-1 promoter. A construct comprising four tandem repeat copies of the -93/-62 region of the PAI-1 promoter linked to CAT was transcriptionally activated in Hep62 cells by insulin. These results outline the central role of MAP kinase activation in the regulation of PAI-1 induced by insulin.

UR - http://www.scopus.com/inward/record.url?scp=0035409351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035409351&partnerID=8YFLogxK

M3 - Article

C2 - 11423472

AN - SCOPUS:0035409351

VL - 50

SP - 1522

EP - 1530

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 7

ER -